The limited duration of the response obtained with BRAF and MEK inhibition in BRAFV600 melanoma and the impressive durability but the relatively low response rate obtained with the block of the immune checkpoint molecules proved to be surprising. The gene discussed is BRAF; the disease is melanoma.